Samuel A Wickline

This inventor holds 43 USPTO granted patents and 5 published patent applications, plus 2 CIPO patents and 5 EPO patents, primarily in Nanoparticle Technology. Top assignees: Barnes Jewish Hospital, Washington University, University of South Florida. Active years: 1997-2026.

USPTO Granted Patents = 43 (Patent Applications = 5)

% Patents Active = 53.5

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 5 (Patent Applications = 8)

Average Co-Inventor Count = 2.8

ph-index = 10

Forward Citations = 565(Granted Patents)

Location History:

St. Louis, MO (US) (1997 - 2020)
Temple Terrace, FL (US) (2021 - 2023)

Company Filing History:

20 out of 36

Barnes Jewish Hospital

patents

19 out of 1,374

Washington University

patents

4 out of 1,982

University of South Florida

patents

4. 3 out of 12

Bristol-Myers Squibb Medical Imaging, Inc.

patents

5. 2 out of 7,680

The Dow Chemical Company

patents

6. 1 out of 838

Philips Electronics North America Corporation

patents

7. 1 out of 7

The Jewish Hospital of St. Louis

patents

where one patent can have more than one assignee

Years Active: 1997-2026

Loading Chart...

Areas of Expertise:

Nanoparticle Delivery

Antithrombotic Nanoparticles

Polynucleotide Transfection

Targeted Drug Delivery

Imaging Agents

Multifunctional Nanoscopy

Ligand-Directed Nanoparticles

Hydrophobic Core

Chelating Agents

Integrin Targeting

Enhanced Ultrasound Detection

ECG Triggered Imaging

43 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12708656 - PEPTIDE-POLYNUCLEOTIDE-HYALURONIC ACID NANOPARTICLES AND METHODS FOR POLYNUCLEOTIDE TRANSFECTION (2026-08-18),

2. 11779544 - Antithrombotic nanoparticles and methods for treating necrotizing enterocolitis (2023-10-10),

3. 11529388 - Peptide-polynucleotide-hyaluronic acid nanoparticles and methods for polynucleotide transfection (2022-12-20),

4. 11337931 - Nanoparticle delivery system for diseases associated with major basement membrane components of blood vessels accessible from blood stream (2022-05-24),

5. 10987315 - Antithrombotic nanoparticles and methods for treating necrotizing enterocolitis (2021-04-27),

6. 10758627 - Peptide-polynucleotide complex for polynucleotide transfection (2020-09-01),

7. 9987371 - Compositions and methods for polynucleotide transfection (2018-06-05),

8. 9808500 - Antithrombotic nanoparticle (2017-11-07),

9. 9764043 - Antithrombotic nanoparticle (2017-09-19),

10. 9468607 - Ligand directed toroidal nanoparticles for therapy and diagnostic imaging (2016-10-18),

11. 9453809 - Multifunctional nanoscopy for imaging cells (2016-09-27),

12. 9446150 - Particles for imaging (2016-09-20),

13. 9415018 - Methods for improving muscle strength (2016-08-16),

14. 9111838 - Method and apparatus for high resolution photon detection based on extraordinary optoconductance (EOC) effects (2015-08-18),

15. 9095521 - Methods for improving muscle strength (2015-08-04),

Title: The Innovator: Samuel A Wickline

Introduction

Samuel A Wickline, a prolific inventor based in St. Louis, MO (US), has made significant contributions to the field of medical nanotechnology. With an impressive portfolio of 42 patents, Wickline is known for his groundbreaking work in developing innovative nanoparticles for medical applications.

Latest Patents

Some of Wickline's latest patents include "Antithrombotic nanoparticles and methods for treating necrotizing enterocolitis", focusing on combating a serious condition, and "Peptide-polynucleotide-hyaluronic acid nanoparticles and methods for polynucleotide transfection", which revolutionizes polynucleotide transfection methods.

Career Highlights

Throughout his career, Wickline has collaborated with renowned institutions such as Barnes Jewish Hospital and Washington University. His tireless dedication to medical research and innovative spirit have led to the development of cutting-edge technologies that have the potential to revolutionize healthcare practices worldwide.

Collaborations

Wickline has worked closely with esteemed professionals in the field, including coworkers Gregory M Lanza and Hua Pan. Together, they have synergized their expertise to push the boundaries of medical nanotechnology and pave the way for future advancements in the industry.

Conclusion

In conclusion, Samuel A Wickline stands as a testament to the power of innovation and perseverance in the field of medical research. His remarkable contributions have not only enhanced our understanding of nanoparticle technology but have also opened new possibilities for transformative treatments in healthcare. Samuel A Wickline's pioneering work continues to inspire and shape the future of medical innovation.